229 related articles for article (PubMed ID: 27471621)
21. IFN-treatment of B16-F1 versus B16-F10: relative impact on non-adaptive and T-cell-mediated immune defense in metastatic spread.
Zöller M
Clin Exp Metastasis; 1988; 6(5):411-29. PubMed ID: 3132343
[TBL] [Abstract][Full Text] [Related]
22. Cytomegalovirus-Based Vaccine Expressing a Modified Tumor Antigen Induces Potent Tumor-Specific CD8(+) T-cell Response and Protects Mice from Melanoma.
Qiu Z; Huang H; Grenier JM; Perez OA; Smilowitz HM; Adler B; Khanna KM
Cancer Immunol Res; 2015 May; 3(5):536-46. PubMed ID: 25633711
[TBL] [Abstract][Full Text] [Related]
23. Vaccination with IL-18 gene-modified, superantigen-coated tumor cells elicits potent antitumor immune response.
Wang Q; Yu H; Zhang L; Ju D; Pan J; Xia D; He L; Wang J; Cao X
J Cancer Res Clin Oncol; 2001 Dec; 127(12):718-26. PubMed ID: 11768611
[TBL] [Abstract][Full Text] [Related]
24. Tumor cells with B7.1 and transmembrane anchored staphylococcal enterotoxin A generate effective antitumor immunity.
Si SY; Hu PZ; Huang YY; Ye J; Huang Y; Li ZS; Ge W; Li X; Qu P; Zhang XM; Sui YF
Biochem Biophys Res Commun; 2006 Aug; 347(1):208-14. PubMed ID: 16814254
[TBL] [Abstract][Full Text] [Related]
25. Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control.
Vianello F; Papeta N; Chen T; Kraft P; White N; Hart WK; Kircher MF; Swart E; Rhee S; Palù G; Irimia D; Toner M; Weissleder R; Poznansky MC
J Immunol; 2006 Mar; 176(5):2902-14. PubMed ID: 16493048
[TBL] [Abstract][Full Text] [Related]
26. Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses.
Lee CH; Chiang YH; Chang SE; Chong CL; Cheng BM; Roffler SR
Clin Cancer Res; 2009 Apr; 15(8):2756-66. PubMed ID: 19318495
[TBL] [Abstract][Full Text] [Related]
27. Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance.
Vijayan S; Sidiq T; Yousuf S; van den Elsen PJ; Kobayashi KS
Immunogenetics; 2019 Mar; 71(3):273-282. PubMed ID: 30706093
[TBL] [Abstract][Full Text] [Related]
28. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
29. The N-terminal domain of NLRC5 confers transcriptional activity for MHC class I and II gene expression.
Neerincx A; Jakobshagen K; Utermöhlen O; Büning H; Steimle V; Kufer TA
J Immunol; 2014 Sep; 193(6):3090-100. PubMed ID: 25127861
[TBL] [Abstract][Full Text] [Related]
30. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors.
Lee JM; Mahtabifard A; Yamada R; Crystal RG; Korst RJ
Clin Cancer Res; 2002 Nov; 8(11):3561-9. PubMed ID: 12429647
[TBL] [Abstract][Full Text] [Related]
31. In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells.
Bellone M; Iezzi G; Manfredi AA; Protti MP; Dellabona P; Casorati G; Rugarli C
Eur J Immunol; 1994 Nov; 24(11):2691-8. PubMed ID: 7525300
[TBL] [Abstract][Full Text] [Related]
32. Murine B16 melanoma vaccination-induced tumor immunity: identification of specific immune cells and functions involved.
Wu TY; Fleischmann WR
J Interferon Cytokine Res; 2001 Dec; 21(12):1117-27. PubMed ID: 11798470
[TBL] [Abstract][Full Text] [Related]
33. Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNgamma primed and IFNbeta treated B7-1+ B16-F10 melanoma cells.
Dezfouli S; Hatzinisiriou I; Ralph SJ
Immunol Cell Biol; 2003 Dec; 81(6):459-71. PubMed ID: 14636243
[TBL] [Abstract][Full Text] [Related]
34. LC3 and NLRC5 interaction inhibits NLRC5-mediated MHC class I antigen presentation pathway in endometrial cancer.
Zhan L; Zhang J; Zhang J; Liu X; Zhu S; Shi Y; He Y; Wang W; Fan Y; Tang Z; Chen G; Wei B; Cao Y
Cancer Lett; 2022 Mar; 529():37-52. PubMed ID: 34974132
[TBL] [Abstract][Full Text] [Related]
35. Expression of B7 co-stimulatory molecules by B16 melanoma results in a natural killer cell-dependent local anti-tumour response, but induces T-cell-dependent systemic immunity only against B7-expressing tumours.
Chong H; Hutchinson G; Hart IR; Vile RG
Br J Cancer; 1998 Oct; 78(8):1043-50. PubMed ID: 9792148
[TBL] [Abstract][Full Text] [Related]
36. Co-expression of P1A35-43/beta2m fusion protein and co-stimulatory molecule CD80 elicits effective anti-tumor immunity in the P815 mouse mastocytoma tumor model.
Zhang X; Mei W; Zhang L; Yu H; Zhao X; Fan X; Qian G; Ge S
Oncol Rep; 2009 Nov; 22(5):1213-20. PubMed ID: 19787242
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of interleukin-15 in vivo enhances antitumor activity against MHC class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T-cell response.
Yajima T; Nishimura H; Wajjwalku W; Harada M; Kuwano H; Yoshikai Y
Int J Cancer; 2002 Jun; 99(4):573-8. PubMed ID: 11992548
[TBL] [Abstract][Full Text] [Related]
38. T-cell receptor gene therapy of established tumors in a murine melanoma model.
Abad JD; Wrzensinski C; Overwijk W; De Witte MA; Jorritsma A; Hsu C; Gattinoni L; Cohen CJ; Paulos CM; Palmer DC; Haanen JB; Schumacher TN; Rosenberg SA; Restifo NP; Morgan RA
J Immunother; 2008 Jan; 31(1):1-6. PubMed ID: 18157006
[TBL] [Abstract][Full Text] [Related]
39. NLRC5 potentiates anti-tumor CD8
Zhang J; Guo B; Chen JH; Liu XJ; Zhang JH; Zhu HQ; Wang WY; Tang ZH; Wei B; Cao YX; Zhan L
Transl Oncol; 2023 Oct; 36():101742. PubMed ID: 37531863
[TBL] [Abstract][Full Text] [Related]
40. Respiratory Syncytial Virus Infection Upregulates NLRC5 and Major Histocompatibility Complex Class I Expression through RIG-I Induction in Airway Epithelial Cells.
Guo X; Liu T; Shi H; Wang J; Ji P; Wang H; Hou Y; Tan RX; Li E
J Virol; 2015 Aug; 89(15):7636-45. PubMed ID: 25972545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
